AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 8689817 — intervention group
Group type: EXPERIMENTAL
Intervention: Racemic terodiline hydrochloride (200 mg)
Number of subjects: 9
Study 8689817 — intervention group
Group type: EXPERIMENTAL
Intervention: S(‐)‐terodiline tartrate (100 mg)
Number of subjects: 9
Study 8689817 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 1718253 — intervention group
Group type: EXPERIMENTAL
Intervention: Perifoveal laser photocoagulation
Number of subjects: 160
Study 1718253 — intervention group
Group type: COMPARATOR
Intervention: Untreated eyes (control)
Number of subjects: 160
Study 6753116 — intervention group
Group type: EXPERIMENTAL
Intervention: Pirenzepine (100 mg/daily)
Number of subjects: 60
Study 6753116 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 30925539 — intervention group
Group type: EXPERIMENTAL
Intervention: Awake Fiberoptic-guided intubation (FGI)
Number of subjects: 46
Study 30925539 — intervention group
Group type: COMPARATOR
Intervention: Awake McGrath videolaryngoscope-guided intubation (VGI)
Number of subjects: 46
Study 30968542 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy with varying extent of lymph node irradiation
Number of subjects: 330
Study 27910185 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel drug-eluting balloon (DEB) angioplasty
Number of subjects: 44
Study 25352613 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention (six-month physical fitness training combined with counseling sessions)
Number of subjects: 0
Study 24402636 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc supplementation (30 mg/day of zinc gluconate for 8 weeks)
Number of subjects: 40
Study 24402636 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 21373904 — intervention group
Group type: EXPERIMENTAL
Intervention: Strong African American Families (SAAF) program
Number of subjects: 332
Study 21373904 — intervention group
Group type: COMPARATOR
Intervention: Control families
Number of subjects: 332
Study 18846551 — intervention group
Group type: EXPERIMENTAL
Intervention: levodopa/carbidopa/entacapone
Number of subjects: 184
Study 17095745 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetazolamide (250 mg every 8 h for 3 days)
Number of subjects: 9
Study 17095745 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetazolamide
Number of subjects: 9
Study 17095745 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 16136932 — intervention group
Group type: EXPERIMENTAL
Intervention: Body acupuncture
Number of subjects: 195
Study 16136932 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined use of ear acupuncture and body acupuncture
Number of subjects: 195
Study 16136932 — intervention group
Group type: COMPARATOR
Intervention: Ear acupuncture
Number of subjects: 195
Study 16136932 — intervention group
Group type: COMPARATOR
Intervention: Simple body acupuncture
Number of subjects: 195
Study 11923554 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrapleural urokinase 40,000 units in 40 ml, administered 12 hourly for 3 days
Number of subjects: 60
Study 11923554 — intervention group
Group type: COMPARATOR
Intervention: Saline (placebo), administered 12 hourly for 3 days
Number of subjects: 60
Study 11923554 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of urokinase and small percutaneous drain
Number of subjects: 60
Study 9813583 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral weight-control intervention (DIET study)
Number of subjects: 247
Study 9813583 — intervention group
Group type: COMPARATOR
Intervention: Wait-listed control community
Number of subjects: 247
Study 7658954 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive Resistance Training (PRT) at 80% or more of 1RM, training twice weekly for 12 months.
Number of subjects: 39
Study 7658954 — intervention group
Group type: COMPARATOR
Intervention: Control Group (CON)
Number of subjects: 39
Study 2576377 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl-nitrous oxide (Group 1)
Number of subjects: 19
Study 2576377 — intervention group
Group type: COMPARATOR
Intervention: Isoflurane-fentanyl-nitrous oxide (Group 2)
Number of subjects: 19
Study 1106447 — intervention group
Group type: EXPERIMENTAL
Intervention: oxazepam (30 mg) and alcohol (0.75 g/kg) combined
Number of subjects: 14
Study 1106447 — intervention group
Group type: EXPERIMENTAL
Intervention: oxazepam (30 mg)
Number of subjects: 14
Study 1106447 — intervention group
Group type: COMPARATOR
Intervention: alcohol (0.75 g/kg)
Number of subjects: 14
Study 1106447 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 14
Study 1106447 — intervention group
Group type: EXPERIMENTAL
Intervention: alcohol given 30 min prior to oxazepam
Number of subjects: 14
Study 31653133 — intervention group
Group type: EXPERIMENTAL
Intervention: Benson relaxation technique
Number of subjects: 120
Study 31653133 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 120
Study 29911784 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum Toxin A (BTXA)
Number of subjects: 25
Study 29911784 — intervention group
Group type: COMPARATOR
Intervention: Corticotherapy (control)
Number of subjects: 25
Study 26036329 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical 30% resin lacquer once daily for 9 months
Number of subjects: 73
Study 26036329 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical 5% amorolfine lacquer once weekly for 9 months
Number of subjects: 73
Study 26036329 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral terbinafine 250 mg once daily for 3 months
Number of subjects: 73
Study 26036329 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral terbinafine
Number of subjects: 73
Study 26036329 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical 30% resin lacquer
Number of subjects: 73
Study 26036329 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical 5% amorolfine lacquer
Number of subjects: 73
Study 26036329 — intervention group
Group type: EXPERIMENTAL
Intervention: Cost-effectiveness
Number of subjects: 73
Study 23819909 — intervention group
Group type: EXPERIMENTAL
Intervention: Cool water immersion (20-24 °C)
Number of subjects: 201
Study 23819909 — intervention group
Group type: COMPARATOR
Intervention: Warm water immersion (37 °C)
Number of subjects: 201
Study 21840914 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive lifestyle intervention
Number of subjects: 92
Study 21840914 — intervention group
Group type: COMPARATOR
Intervention: Brief advice (control)
Number of subjects: 92
Study 20084896 — intervention group
Group type: EXPERIMENTAL
Intervention: rBS/WC oral cholera vaccine
Number of subjects: 3041
Study 20084896 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3041
Study 16680923 — intervention group
Group type: EXPERIMENTAL
Intervention: Mometasone furoate DPI, 200 microg, once daily in the evening
Number of subjects: 0
Study 16680923 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 15166553 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol alone
Number of subjects: 20
Study 15166553 — intervention group
Group type: COMPARATOR
Intervention: Remifentanil alone
Number of subjects: 20
Study 15166553 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol with modest remifentanil concentrations
Number of subjects: 20
Study 15166553 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of propofol and remifentanil
Number of subjects: 20
Study 11822519 — intervention group
Group type: EXPERIMENTAL
Intervention: Research-based teaching programme
Number of subjects: 16
Study 11822519 — intervention group
Group type: COMPARATOR
Intervention: Baseline knowledge and practice
Number of subjects: 16
Study 9726718 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerosolized terbutaline, 400 microg q6h
Number of subjects: 8
Study 9726718 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 8028519 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training (primarily running)
Number of subjects: 130
Study 8028519 — intervention group
Group type: EXPERIMENTAL
Intervention: Caloric restriction (dieting)
Number of subjects: 130
Study 8028519 — intervention group
Group type: COMPARATOR
Intervention: Sedentary, nondieting controls
Number of subjects: 130
Study 2663386 — intervention group
Group type: EXPERIMENTAL
Intervention: External shock-wave lithotripsy (ESL) and adjuvant ursodiol therapy
Number of subjects: 223
Study 2663386 — intervention group
Group type: COMPARATOR
Intervention: Ursodiol therapy alone
Number of subjects: 223
Study 4574639 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 weeks cyclophosphamide therapy
Number of subjects: 32
Study 4574639 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 weeks cyclophosphamide therapy
Number of subjects: 32
Study 4574639 — intervention group
Group type: COMPARATOR
Intervention: steroid treatment alone
Number of subjects: 32
Study 29600726 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic Training + Resistance Training (AT+RT)
Number of subjects: 73
Study 29600726 — intervention group
Group type: COMPARATOR
Intervention: Aerobic Training (AT)
Number of subjects: 73
Study 27966565 — intervention group
Group type: EXPERIMENTAL
Intervention: Inulin (24g)
Number of subjects: 25
Study 27966565 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistant Starch (28g)
Number of subjects: 25
Study 27966565 — intervention group
Group type: COMPARATOR
Intervention: Control (75g glucose)
Number of subjects: 25
Study 25370206 — intervention group
Group type: EXPERIMENTAL
Intervention: 20-mg tadalafil
Number of subjects: 383
Study 25370206 — intervention group
Group type: EXPERIMENTAL
Intervention: 100-mg sildenafil
Number of subjects: 383
Study 23847252 — intervention group
Group type: EXPERIMENTAL
Intervention: Model-based iterative reconstruction (MBIR)
Number of subjects: 51
Study 23847252 — intervention group
Group type: COMPARATOR
Intervention: Adaptive statistical iterative reconstruction (ASIR)
Number of subjects: 51
Study 21640360 — intervention group
Group type: EXPERIMENTAL
Intervention: Essential PUFA from flaxseed oil
Number of subjects: 51
Study 21640360 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-chain PUFA from fish oil
Number of subjects: 51
Study 21640360 — intervention group
Group type: COMPARATOR
Intervention: Soybean oil (Control)
Number of subjects: 51
Study 18963025 — intervention group
Group type: EXPERIMENTAL
Intervention: IFN‐beta treated patients in remission
Number of subjects: 117
Study 18963025 — intervention group
Group type: COMPARATOR
Intervention: Untreated patients with MS relapse
Number of subjects: 117
Study 16880095 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenosine triphosphate stress strain imaging
Number of subjects: 34
Study 16880095 — intervention group
Group type: COMPARATOR
Intervention: Control group (no LAD lesions)
Number of subjects: 34
Study 16880095 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary flow velocity reserve measurement
Number of subjects: 34
Study 12964783 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary intervention for 6 months
Number of subjects: 180
Study 12964783 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 180
Study 10567758 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-step gait initiation protocol
Number of subjects: 25
Study 10567758 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-step gait termination protocol
Number of subjects: 25
Study 10567758 — intervention group
Group type: COMPARATOR
Intervention: Midgait protocol
Number of subjects: 25
Study 8696724 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative radiotherapy (3000 cGy in 2 weeks)
Number of subjects: 74
Study 8696724 — intervention group
Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 74
Study 8696724 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative radiotherapy
Number of subjects: 74
Study 8696724 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative radiotherapy and surgery
Number of subjects: 74
Study 2249406 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mgF- tablets plus fortnightly rinsing at school with 1000 ppmF-
Number of subjects: 192
Study 2249406 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mgF- tablets plus placebo rinsing
Number of subjects: 192
Study 2249406 — intervention group
Group type: COMPARATOR
Intervention: Placebo tablets plus 1000 ppmF- rinsing
Number of subjects: 192
Study 2249406 — intervention group
Group type: EXPERIMENTAL
Intervention: Active tablet/active rinse group
Number of subjects: 192
Study 2249406 — intervention group
Group type: EXPERIMENTAL
Intervention: Active tablet/placebo rinse group
Number of subjects: 192
Study 2249406 — intervention group
Group type: COMPARATOR
Intervention: Tablet-only children
Number of subjects: 192
Study 6996417 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonic measurement of fetal chest area between 32 and 36 weeks of gestation (Group A)
Number of subjects: 745
Study 6996417 — intervention group
Group type: COMPARATOR
Intervention: Control group (Group B)
Number of subjects: 745
Study 6996417 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonic measurement of fetal chest area (Group A)
Number of subjects: 745
Study 30730346 — intervention group
Group type: EXPERIMENTAL
Intervention: Intradermal Botulinum Toxin (BTX) injections
Number of subjects: 24
Study 30730346 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (control)
Number of subjects: 24
Study 28126300 — intervention group
Group type: COMPARATOR
Intervention: Short-Term Androgen Deprivation (STAD)
Number of subjects: 133
Study 28126300 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-Term Androgen Deprivation (LTAD)
Number of subjects: 133
Study 25510839 — intervention group
Group type: EXPERIMENTAL
Intervention: β-Alanine (BA)
Number of subjects: 18
Study 25510839 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 18
Study 24481564 — intervention group
Group type: EXPERIMENTAL
Intervention: Video message about amniocentesis and chorionic villus sampling
Number of subjects: 176
Study 24481564 — intervention group
Group type: EXPERIMENTAL
Intervention: Audio message about amniocentesis and chorionic villus sampling
Number of subjects: 176
Study 24481564 — intervention group
Group type: COMPARATOR
Intervention: Text message about amniocentesis and chorionic villus sampling
Number of subjects: 176
Study 23095307 — intervention group
Group type: EXPERIMENTAL
Intervention: adalimumab 40 mg/2 weeks
Number of subjects: 32
Study 23095307 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 32
Study 21172842 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyurea (HU) 20 mg/kg/day
Number of subjects: 55
Study 21172842 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study 17652181 — intervention group
Group type: EXPERIMENTAL
Intervention: Cinacalcet 50 mg orally once daily for 8 days
Number of subjects: 0
Study 17652181 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 16324031 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (0.2 microg.kg(‐1).h(‐1))
Number of subjects: 50
Study 16324031 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 50
Study 11896478 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxazosin (4 mg daily) and sildenafil (100 mg 1 h before sexual intercourse)
Number of subjects: 28
Study 11896478 — intervention group
Group type: COMPARATOR
Intervention: Sildenafil and placebo
Number of subjects: 28
Study 10213258 — intervention group
Group type: EXPERIMENTAL
Intervention: Surfactant treatment (S)
Number of subjects: 40
Study 10213258 — intervention group
Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 40
Study 8750026 — intervention group
Group type: EXPERIMENTAL
Intervention: Right hand aiming at perturbed target (target jumped 3 cm to the right or left)
Number of subjects: 10
Study 8750026 — intervention group
Group type: EXPERIMENTAL
Intervention: Left hand aiming at perturbed target (target jumped 3 cm to the right or left)
Number of subjects: 10
Study 8750026 — intervention group
Group type: COMPARATOR
Intervention: Control condition (stationary target)
Number of subjects: 10
Study 3042876 — intervention group
Group type: EXPERIMENTAL
Intervention: BS-WC vaccine
Number of subjects: 24770
Study 3042876 — intervention group
Group type: COMPARATOR
Intervention: WC vaccine
Number of subjects: 24770
Study 31166697 — intervention group
Group type: EXPERIMENTAL
Intervention: Lasmiditan 50 mg
Number of subjects: 1262
Study 31166697 — intervention group
Group type: EXPERIMENTAL
Intervention: Lasmiditan 100 mg
Number of subjects: 1262
Study 31166697 — intervention group
Group type: EXPERIMENTAL
Intervention: Lasmiditan 200 mg
Number of subjects: 1262
Study 31166697 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1262
Study 28100551 — intervention group
Group type: EXPERIMENTAL
Intervention: Nintedanib (intervention in a 12-month, randomized, placebo-controlled trial)
Number of subjects: 428
Study 26619338 — intervention group
Group type: EXPERIMENTAL
Intervention: Community based peer counselling (in addition to standard health facility breastfeeding promotion services)
Number of subjects: 0
Study 26619338 — intervention group
Group type: COMPARATOR
Intervention: Standard health facility breastfeeding promotion services (HFP) alone
Number of subjects: 0
Study 26619338 — intervention group
Group type: EXPERIMENTAL
Intervention: Community based peer counselling
Number of subjects: 0
Study 24377642 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 lessons smoking prevention program
Number of subjects: 55
Study 24377642 — intervention group
Group type: COMPARATOR
Intervention: Standard anti-smoking education
Number of subjects: 55
Study 21168840 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual aid depicting clean and dirty colons in addition to standard written instructions
Number of subjects: 969
Study 21168840 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard written instructions only)
Number of subjects: 969
Study 21168840 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual aid group
Number of subjects: 969
Study 19064822 — intervention group
Group type: EXPERIMENTAL
Intervention: Half-dose TIV
Number of subjects: 1114
Study 19064822 — intervention group
Group type: COMPARATOR
Intervention: Full-dose TIV
Number of subjects: 1114
Study 19499272 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifaceted intervention (screening and patient education) by community pharmacists
Number of subjects: 262
Study 19499272 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 262
Study 16100237 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol 2 mg kg(‐1) in isotonic saline 0.2 ml kg(‐1)
Number of subjects: 80
Study 16100237 — intervention group
Group type: COMPARATOR
Intervention: Morphine 0.1 mg kg(‐1) in isotonic saline 0.2 ml kg(‐1)
Number of subjects: 80
Study 11966493 — intervention group
Group type: EXPERIMENTAL
Intervention: Baclofen 40 mg
Number of subjects: 20
Study 9710008 — intervention group
Group type: EXPERIMENTAL
Intervention: Diuretic (trichlormethiazide, 2 mg daily)
Number of subjects: 73
Study 9710008 — intervention group
Group type: EXPERIMENTAL
Intervention: NSAID-slow release (tenoxicam-SR, 20 mg daily)
Number of subjects: 73
Study 9710008 — intervention group
Group type: EXPERIMENTAL
Intervention: Steroid (prednisolone, 20 mg daily for 2 weeks, then 10 mg daily for 2 weeks)
Number of subjects: 73
Study 9710008 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 73
Study 7799337 — intervention group
Group type: EXPERIMENTAL
Intervention: Chrysotherapy
Number of subjects: 0
Study 7799337 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucocorticoids
Number of subjects: 0
Study 7799337 — intervention group
Group type: EXPERIMENTAL
Intervention: Gold alone
Number of subjects: 0
Study 2841905 — intervention group
Group type: EXPERIMENTAL
Intervention: Carboplatin 300 mg/m2
Number of subjects: 30
Study 2841905 — intervention group
Group type: EXPERIMENTAL
Intervention: Carboplatin 400 mg/m2
Number of subjects: 30
Study 2841905 — intervention group
Group type: EXPERIMENTAL
Intervention: Carboplatin 450 mg/m2
Number of subjects: 30
Study 2841905 — intervention group
Group type: EXPERIMENTAL
Intervention: Carboplatin (all doses)
Number of subjects: 30
Study 1244812 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium heparinate (low doses, administered subcutaneously)
Number of subjects: 100
Study 1244812 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium pentosan polysulfate (administered intramuscularly)
Number of subjects: 100
Study 1244812 — intervention group
Group type: COMPARATOR
Intervention: Untreated control group
Number of subjects: 100
Study 30851623 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise Program (EP)
Number of subjects: 35
Study 30851623 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 35
Study 30396605 — intervention group
Group type: EXPERIMENTAL
Intervention: Connective Tissue Manipulation (CTM)
Number of subjects: 44
Study 30396605 — intervention group
Group type: COMPARATOR
Intervention: Control group (advising only)
Number of subjects: 44
Study 26518596 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep
Number of subjects: 60
Study 26518596 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep Deprivation
Number of subjects: 60
Study 26518596 — intervention group
Group type: COMPARATOR
Intervention: Daytime Wakefulness
Number of subjects: 60
Study 25146365 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine camsylate/losartan 5/100 mg/d (AML/LOS)
Number of subjects: 199
Study 25146365 — intervention group
Group type: COMPARATOR
Intervention: Losartan/hydrochlorothiazide 100/12.5 mg/d (LOS/HCTZ)
Number of subjects: 199
Study 21592715 — intervention group
Group type: EXPERIMENTAL
Intervention: Ongoing group based diabetes self-management education (DSME)
Number of subjects: 146
Study 21592715 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control
Number of subjects: 146
Study 21180793 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoride-containing toothpastes
Number of subjects: 206
Study 20664127 — intervention group
Group type: EXPERIMENTAL
Intervention: Humor group (self-selected humor for 30 minutes daily)
Number of subjects: 48
Study 20664127 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard cardiac therapy)
Number of subjects: 48
Study 15458908 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene 60 mg/d or 120 mg/d
Number of subjects: 7705
Study 11167350 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetirizine (C) 10 mg daily for 2 weeks
Number of subjects: 12
Study 11167350 — intervention group
Group type: COMPARATOR
Intervention: Placebo (P) for 2 weeks
Number of subjects: 12